DoW Pancreatic Cancer Research Program, Translational Research Partnership Award

Summary

Summary: The fiscal year 2026 (FY26) Pancreatic Cancer Research Program (PCARP) Translational Research Partnership Award supports partnerships between clinicians, population scientists, applied scientists and/or basic scientists that will accelerate the movement of promising ideas in pancreatic cancer toward clinical applications. The partnership must include at least one member with expertise in pancreatic cancer research or pancreatic cancer patient care. All applications must address at least one of the FY26 PCARP Focus Areas . · This award mechanism requires preliminary data to support feasibility of the research hypothesis(es) and research approaches. However, these data do not necessarily need to originate from studies of pancreatic cancer. Applications can support retrospective tissue analysis, correlative studies and pilot clinical trials; however, this mechanism does not allow large-scale clinical trials. · The Translational Research Partnership Award requires two Principal Investigators (PIs) referred to as the Initiating PI and the Partnering PI . Only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. The partnering PI’s application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.